AMRI reports that its facility in Buffalo, New York has been selected to participate as a Dedicated Chemical Biology Consortium  Center for the Experimental Therapeutics (NExT) Program, centered at the Frederick National Laboratory for Cancer Research.

The Frederick National Lab, sponsored by the National Cancer Institute (NCI), is managing the expansion of the Chemical Biology Consortium to 22 sites around the country with expertise in high-throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and animal models for oncology. AMRI is participating in the consortium via a research subcontract from Leidos Biomedical Research, Inc., the prime contractor for the national lab.

The Chemical Biology Consortium is the discovery engine for the NCI Experimental Therapeutics (NExT) Program focused on advancing new cancer therapeutics against novel molecular and genetic cancer targets. AMRI’s Buffalo facility will provide a variety of drug-discovery services to the consortium for a period of five years. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug-discovery and development projects. The NCI partners with companies to facilitate the milestone-driven progression of new anticancer drugs (small molecules and biologics) and imaging agents toward clinical evaluation and registration.

AMRI’s integrated drug discovery center in Buffalo comprises biologists, medicinal chemists, and pharmacologists with specific experience in the area of oncology, antibacterials, and neurodegenerative disorders. Through collaborative partnerships, AMRI’s integrated drug-discovery center provides a variety of technologies that include proprietary informatics to enable increased data analysis for accelerated process development. AMRI’s drug- discovery expertise includes protein production and purification, high throughput screening, cancer cell biology, chemistry and compound profiling, as well as scale-up synthesis and formulation to support in vivo studies.

Source: AMRI